Uqora Conducts Two Clinical Trials, Advancing Urinary Health Research

Uqora's Urinary Health Products
Uqora’s lineup of Urinary Health Products

Urinary tract infections (UTIs) affect half of all women and are the second most common infection in the U.S. Despite this, UTI prevention is chronically underfunded and under-researched. Uqora wants to change that. Uqora, maker of urinary tract health products, believes firmly in its mission to address urinary tract health in innovative and effective ways. Uqora products are developed alongside urologists and physicians using science-backed ingredients to bring to market urinary tract health solutions that work

Founder Jenna Ryan has herself been stuck in the awful recurrent UTI cycle and understands the problem from personal experience. When best-practice solutions like drinking cranberry juice and urinating after sex did not work, Jenna and her partner Spencer Gordon decided to work together to find a better solution. With Gordon’s background in biochemistry and armed with the best research, they teamed up with physicians and urologists to develop Uqora’s product line. Uqora has now helped over 75,000 people with their urinary tract health. 

Committed to expanding research into urinary health, Uqora is partnering with third-party research groups Hawthorne Effect and the George Washington University Medical Faculty Associates Urology Clinic for two upcoming clinical trials. These trials aim to advance research and solutions for UTI preventatives. 

Uqora and Urinary Health in Women with Recurring UTIs

Research group Hawthorne Effect and Uqora are partnering together for a 360 subject double-blind, placebo-controlled clinical trial to advance research on effective UTI prevention. Uqora is eager to build more research around preventative solutions for urinary tract health, a major public health issue. This study will measure the reduction of UTIs with the help of Uqora’s preventative products. 

The study’s subjects will be women over 18 years old who have been treated for two or more UTIs in the past six months and are in otherwise good health. The participants of this study will be broken up into three groups. The Control – Placebo group will take one placebo drink mix and two placebo capsules daily for 180 days. Group 1 will take one Uqora drink mix and two placebo capsules daily for 180 days. Finally, Group 2 will take one Uqora drink mix and two Uqora capsules daily for 180 days. Data from this study will be available in the second half of 2020. 

George Washington University Urology Clinical Trial on Uqora and UTI Prevention

Uqora has also teamed up with the George Washington University Medical Faculty Associates Urology Clinic for a clinical trial. This study will demonstrate the effectiveness of Uqora’s intervention products, which are designed to reduce the recurrence of urinary tract infections in healthy women with a history of UTIs. Like the previous study mentioned led by Hawthorne Effect, this is also a randomized, double-blind, placebo-controlled trial. This is the second randomized controlled study to determine the efficacy of Uqora’s products. 

The study will have 240 total subjects over 18 years old who will take either a placebo or an active study Uqora product once daily over 12 months. Those eligible are women in good health with no active immunosuppression or current UTI symptoms who have had at least three symptomatic UTIs in the past year that required a doctor’s visit, one episode of which must be culture confirmed. The study will measure the frequency of recurrent UTIs over 12 months. A UTI episode will be defined as having at least one UTI symptom. All results will be confirmed by urine culture.

Urinary tract infections impact mostly women, but research on conditions that primarily affect women continues to be scarce in the medical community. Uqora is excited to contribute to this important area of study to make sure that women’s health issues receive the funding and research they deserve. Uqora’s two clinical trials will advance research and funding in the urinary health space, an often overlooked area of study. 

Seeking Alternatives to Antibiotics 

The most common method to treat UTIs has traditionally been antibiotics. However, because people have relied on antibiotics for so long, their effectiveness has begun to decline. Antibiotic resistance and dependency have become a growing concern in the treatment of UTIs in particular. The number of antibiotic-resistant UTIs has doubled from 8 percent to 15 percent in the last 10 years. 

Antibiotics are some of the most commonly prescribed drugs, and UTIs are one of the leading causes of antibiotic use. While antibiotics are lifesaving drugs, 50 percent of the time, antibiotics are prescribed when not needed or with the incorrect dosing or duration, according to the Centers for Disease Control (CDC). While antibiotics are sometimes required to treat UTIs, they’re often prescribed for preventative purposes as well. Of the women surveyed by Uqora, more than half have taken prophylactic antibiotics for UTI treatment.

Uqora’s clinical trials will provide some much needed data to further innovation in urinary tract health. Uqora believes in prevention methods that reduce the use of antibiotic solutions for UTIs and improve urinary tract health. 

More About Uqora’s Products

Containing no medications or antibiotics, Uqora offers a three-step system for promoting urinary health: Target, Control, and Promote. 


Target’s purpose is to flush out new bacteria. This product is recommended for those who are sexually active or want to flush the urinary tract. The ingredients in Target bind with bacteria, increasing urinary flow to push the bacteria out of your system. Using Target alkalizes urine, making it harder for bacteria to grow and boosts immune system function.

Take Target by mixing one packet in 8–12 ounces of water after sex, exercise, travel, or holding your bladder. For those not sexually active, taking Target every three days will regularly flush out bacteria.


Control is designed to cleanse biofilm that may build up in the urinary tract. Biofilm is a cluster of grouped bacterial cells that stick to the bladder wall. These bacterial cells produce a protective film that shields them from antibiotics and your body’s natural defenses. Control breaks up biofilm to keep you in the clear.

Take two capsules of Control daily with water to manage any biofilm buildup. 


Promote is formulated to include two probiotic strains clinically proven to maintain and restore good vaginal bacteria (Lactobacillus rhamnosus, Lactobacillus reuteri and Lactobacillus acidophilus). A key component to proper urinary health is maintaining a healthy vaginal microbiome. When the vaginal microbiome is not in balance, it threatens the urinary microbiome as well. 

Take one capsule of Promote daily to maintain a balanced microbiome. 

Uqora products are designed to be taken all together as a system to target specific areas that all work to promote urinary tract health. They may all three be taken on the same day, or you can choose which product is best for you depending on your needs. Uqora products contain no antibiotics and offer an alternative solution. 

The Future of Urinary Health

Committed to raising the bar on urinary tract health and in search of innovative preventative solutions, Uqora is hopeful that both the Hawthorne Effect and George Washington University clinical trials will raise the bar for women’s health research and advance funding in the urinary health space. Often overlooked, underfunded, and under-researched, the area of UTI prevention and treatment is ripe for innovation. The research gathered from these clinical trials will help the Uqora team develop better products and provide a more thorough understanding of effective UTI prevention. Uqora, having already helped 75,000 people with urinary tract health products, is thrilled to be at the forefront of this important research. For the latest on Uqora follow their Linkedin and Youtube.

More on Health Source Magazine